{
    "2019-05-21": [
        [
            {
                "time": "2018-05-21",
                "original_text": "Top Ranked Income Stocks to Buy for May 21st",
                "features": {
                    "keywords": [
                        "income stocks",
                        "buy",
                        "May"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-21",
                "original_text": "3 Top Dividend Stocks to Buy Right Now",
                "features": {
                    "keywords": [
                        "dividend stocks",
                        "buy",
                        "right now"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-21",
                "original_text": "Better Buy: AbbVie vs. Pfizer",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Pfizer",
                        "better buy"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-21",
                "original_text": "AbbVie Launches ORILISSAâ„¢ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "ORILISSA",
                        "elagolix",
                        "endometriosis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}